- Home
- WGRX vs NRSN Comparison
WGRX vs NRSN Comparison
Compare WGRX & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WGRX | NRSN |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | United States | Israel |
| Employees | N/A | 15 |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 24.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WGRX | NRSN |
|---|---|---|
| Price | $0.13 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 10.9M | 98.8K |
| Earning Date | 05-11-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.63 |
| 52 Week High | $7.04 | $2.60 |
Technical Indicators
Market Signals| Indicator | WGRX | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 50.72 |
| Support Level | $0.10 | $0.68 |
| Resistance Level | $0.17 | $0.86 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 46.45 | 52.07 |
Price Performance
Historical ComparisonAbout WGRX Wellgistics Health Inc.
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.